Use of phosphodiesterase 4 inhibitor in patients with psoriatic arthritis
https://doi.org/10.14412/1996-7012-2017-2-75-79
Abstract
Psoriatic arthritis (PsA) is a chronic inflammatory disease of the joints, spine, and entheses, which is associated with psoriasis. The pathological process is localized mainly in the tissues of the locomotor system and leads to the development of erosive arthritis, intra-articular osteolysis, and spondyloarthritis. Nonsteroidal anti-inflammatory drugs, glucocorticoids, disease-modifying antirheumatic drugs (DMARDs), biological agents (BAs), and targeted synthetic drugs (or signaling pathway blockers) are used to treat PsA. The latter group of drugs includes apremilast, a phosphodiesterase 4 inhibitor. Recent data of controlled studies suggest that apremilast is effective and safe in treating psoriasis and PsA. Prospects for the use of apremilast in PsA are associated with the possibility of giving the drug to patients because of the inefficacy of DMARDs or BAs.
About the Authors
V. I. Mazurov
I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg
Russian Federation
Russian Federation
E. A. Trofimov
I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg
Russian Federation
Russian Federation
References
1. McGonagle DG, Helliwell P, Veale D. Enthesitis in psoriatic disease. Dermatology. 2012;225(2):100-9. doi: 10.1159/000341536. Epub 2012 Oct 27.
2. Мазуров ВИ, Трофимов ЕА. Ревматология. Фармакотерапия без ошибок: руководство для врачей. Москва: Е-ното; 2017. 528 с. [Mazurov VI, Trofimov EA. Revmatologiya. Farmakoterapiya bez oshibok: rukovodstvo dlya vrachei [Rheumatology. Pharmacotherapy without errors: a guide for physicians]. Moscow: E-noto; 2017. 528 p.].
3. Dattola A, Del Duca E, Saraceno R, et al. Safety evaluation of apremilast for the treatment of psoriasis. Expert Opin Drug Saf. 2017 Mar;16(3):381-385. doi: 10.1080/14740338. 2017.1288714. Epub 2017 Feb 7.
4. Aldredge LM, Young MS. Providing guidance for patients with moderate-to-severe psoriasis who are candidates for biologic therapy: Role of the nurse practitioner and physician assistant. J Dermatol Nurses Assoc. 2016 Jan;8(1):14-26. Epub 2016 Feb 12.
5. Healy PJ, Groves C, Chandramohan M, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Rheumatology (Oxford). 2008 Jan;47(1):92-5.
6. Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011 Jun;25 Suppl 4:9-14. doi: 10.1111/j.1468-3083. 2011.04060.x.
7. Blome C, Gosau R, Radtke MA, et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res. 2016 Mar;308(2):69-78. doi: 10.1007/s00403-015-1613-8. Epub 2015 Dec 19.
8. Wendling D, Prati C. Targeted synthetic disease-modifying antirheumatic drugs in spondyloarthritis. Immunotherapy. 2017 Mar;9(3):221-223. doi: 10.2217/imt- 2017-0001.
9. Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: Exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93): S2-6. Epub 2015 Oct 15.
10. Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: Findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol. 2013 Oct;149(10):1180-5. doi: 10.1001/jamadermatol.2013.5264.
11. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis. J Rheumatol. 2015 Mar;42(3): 479-88. doi: 10.3899/jrheum.140647. Epub 2015 Jan 15.
12. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015 Jul;73(1):37-49. doi: 10.1016/j.jaad.2015.03.049.
13. Paul C, Cather J, Gooderham M, et al.Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: A phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015 Dec;173(6):1387-99. doi: 10.1111/bjd.14164. Epub 2015 Nov 7.
14. Reich K, Sobell J, Day R, et al. Change in weight with apremilast, an oral phosphodiesterase 4 inhibitor: Pooled analysis of the ESTEEM 1 and ESTEEM 2 trials. 73rd Annual Meeting of the American Academy of Dermatology: San Francisco; 2015.
15. Reich K, Papp K, Gordon K, et al. Longterm safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis of two phase 3, randomized, controlled trials (ESTEEM 1 and 2). Summer Academy Meeting of the American Academy of Dermatology: New York; 2015.
Review
For citations:
Mazurov VI, Trofimov EA. Use of phosphodiesterase 4 inhibitor in patients with psoriatic arthritis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2017;11(2):75-79. (In Russ.) https://doi.org/10.14412/1996-7012-2017-2-75-79
Views:
3298
Email this article 